Strategic partnerships Zymeworks has active collaborations and licenses surrounding Ziihera with BeOne Medicines and Jazz Pharmaceuticals Ireland, indicating a strong partner-ready route for co-development or regional commercialization opportunities in HER2-targeted therapies.

Pipeline expansion The company is advancing multispecific antibodies and antibody-drug conjugates through an integrated R&D engine, presenting multiple near-term selling points for find-and-refer opportunities across difficult-to-treat cancers and autoimmune diseases.

Recent M&A activity Acquisition of Theravance for US$929M signals aggressive growth and expanded capabilities, suggesting new cross-selling opportunities forTheravance’s and Zymeworks’ combined portfolios, as well as increased interest from investors and strategic buyers.

Key senior engagement Leadership participates in major conferences (Morgan Stanley, H.C. Wainwright, Biopharma Back to School Summit), creating frequent touchpoints for investor and strategic conversations; leverage speaking schedules to coordinate outbound outreach and partnership pitches.

Advanced tech partnership Gandeeva Therapeutics collaboration to visualize antibody-antigen interfaces with cryo-EM highlights a potential for joint discovery services or co-development opportunities around structural biology capabilities and accelerated design.